Nanogam (intravenous normal human immunoglobulin) / Sanquin - LARVOL DELTA

Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial (clinicaltrialsregister.eu) - P1/2 | N=48 | Completed | Sponsor: Stichting Amsterdam UMC | Active, not recruiting ➔ Completed

Trial completion • Immunology • Myositis

TIMEISMUSCLE: Add-on Intravenous Immunoglobulins in Early Myositis (clinicaltrials.gov) - P2/3 | N=44 | Active, not recruiting | Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Recruiting ➔ Active, not recruiting | Phase classification: P2 ➔ P2/3 | Trial completion date: Sep 2024 ➔ Jul 2026 | Trial primary completion date: Feb 2024 ➔ Sep 2025

Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Dermatomyositis • Immunology • Myositis • Rare Diseases

Combined Use of Immunoglobulin and Pulse Steroid Therapies in Severe Covid-19 Patients (clinicaltrials.gov) - P4 | N=178 | Completed | Sponsor: Konya City Hospital

New P4 trial • Critical care • Infectious Disease • Novel Coronavirus Disease

An infusion of antibodies to COVID-19 for patients with B cell disorder, a randomized (randomized) study (COVID Compromise study). (clinicaltrialsregister.eu) - P3; N=86; Ongoing; Sponsor: Amsterdam UMC

Clinical • New P3 trial • Infectious Disease • Multiple Myeloma • Novel Coronavirus Disease • Respiratory Diseases • CD20

Borrelia burgdorferi sensu lato seroconversion after intravenous immunoglobulin treatment: a cohort study. (PubMed, Eur J Neurol) - "Transient presence of anti-Bbsl IgG antibodies after IVIg is regularly observed. This effect appears to be dependent on the IVIg brand, probably reflecting variation in Bbsl exposure of plasma donors. Lyme borreliosis serological testing during, and weeks to months after IVIg, is therefore of limited utility."

Journal • Immunology • Inflammatory Arthritis • Lyme Disease • Myositis • Pain

The ConvP COVig PKPD study: an investigation for the use of plasma or antibodies against the novel coronavirus (SARS-CoV-2) De ConvP COVig PKPD studie: een onderzoek naar nuttig gebruik van plasma of antilichamen voor behandeling van het nieuwe coronavirus (SARS-CoV-2) (clinicaltrialsregister.eu) - P1/2; N=104; Ongoing; Sponsor: Erasmus MC

New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases